Advertisement
This ad is displayed using third party content and we do not control its accessibility features.
Close Banner
Advertisement
This ad is displayed using third party content and we do not control its accessibility features.

Study Reveals Why Many Lyme Patients Still Have Joint Pain After Treatment

Stephanie Eckelkamp
Author:
June 17, 2019
Stephanie Eckelkamp
Contributing Health & Nutrition Editor
By Stephanie Eckelkamp
Contributing Health & Nutrition Editor
Stephanie Eckelkamp is a writer and editor who has been working for leading health publications for the past 10 years. She received her B.S. in journalism from Syracuse University with a minor in nutrition.
Image by BONNINSTUDIO / Stocksy
June 17, 2019

Many people who have (or suspect they may have) late-stage or chronic Lyme disease end up with debilitating joint pain and even full-blown Lyme arthritis. And for some of these people, symptoms don't fade even with antibiotic treatment. But now, researchers seem to have identified a potential cause—which means more effective treatment may not be far behind.

In a new study published in the Proceedings of the National Academy of Sciences, researchers discovered that as Lyme-causing bacteria (Borrelia burgdorferi) multiplies, it sheds a cellular component called peptidoglycan, which triggers a unique inflammatory response in the body that leads to symptoms of joint pain and Lyme arthritis.

Researchers identified peptidoglycan in samples of synovial fluid (aka joint fluid) from patients with confirmed cases of Lyme disease whose symptoms were not responding to antibiotic treatment. "We can actually detect peptidoglycan in the synovial fluid of the affected, inflamed joints of patients that have all the symptoms of Lyme arthritis but no longer have an obvious, active infection," said study author and assistant professor of biochemistry Brandon Jutras, Ph.D., in a news release.

To confirm that the peptidoglycan was, in fact, capable of contributing to arthritis on its own, researchers purified the synovial fluid samples (to eliminate all other bacterial components) and injected them into mice. Within 24 hours, the mice experienced dramatic joint inflammation—indicating that the peptidoglycan was to blame.

Because peptidoglycan persists in the synovial fluid and is not easily eliminated, the immune system may continue to mount an inflammatory response to it—which is why joint pain may remain even after the Lyme infection is treated with antibiotics. This may be exacerbated by a number of factors, like certain genetic predispositions or the state of the immune system.

This discovery is great news, as it opens up the door for more targeted treatments for late-stage Lyme arthritis symptoms (and potentially other late-stage Lyme symptoms). Jutras and other researchers are now looking into ways to destroy peptidoglycan, or counter the body's response to it.

This discovery could also potentially help confirm Lyme disease diagnoses. While all bacteria contain some form of peptidoglycan, the type found in Lyme bacteria has a unique chemical structure—so doctors could theoretically test a patient's synovial fluid for the presence of this particular peptidoglycan as a way to confirm an inconclusive Lyme diagnostic blood test.

More On This Topic

more Health
Advertisement
This ad is displayed using third party content and we do not control its accessibility features.
Advertisement
This ad is displayed using third party content and we do not control its accessibility features.